Effects of etelcalcetide and teriparatide on bone in chronic kidney disease model rats

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09450
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56020:Orthopedics-related
• Research Institution: Akita University
• Principal Investigator: Hongo Michio 秋田大学, 医学系研究科, 教授 (50375250)
• Co-Investigator(Kenkyū-buntansha): 宮腰 尚久 秋田大学, 医学系研究科, 教授 (90302273) ; 粕川 雄司 秋田大学, 医学部附属病院, 准教授 (60375285) ; 石川 慶紀 秋田大学, 医学部附属病院, 助教 (00566151) ; 土江 博幸 秋田大学, 医学部附属病院, 助教 (80513019)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 骨粗鬆症 / 慢性腎臓病 / 薬物治療

Outline of Final Research Achievements

In the first study, we investigated how bone mineral density, bone strength, bone microstructure, and renal damage change over time in a Stage IV rat model of chronic kidney disease (CKD). We observed the changes over time using various methods. As a result, in CKD model rats with persistent renal impairment corresponding to CKD stage IV, decreased bone density and strength of cancellous and cortical bone persisted. In the next study, we examined the combined effect of etelcalcetide (EC) and teriparatide (TPTD) on bone in CKD model rats. Concomitant use of TPTD decreased serum Ca and increased bone density and strength of the femur.

Free Research Field

骨粗鬆症

Academic Significance and Societal Importance of the Research Achievements

本研究では，慢性腎臓病における骨代謝の詳細が明らかになり，さらに薬物治療効果について明らかにすることができた．この結果は骨粗鬆症を伴う慢性腎臓病患者の治療法の発展に寄与するものと考えられる．